 RUTHERFORD, N.J., Feb. 10, 2021 GLOBE NEWSWIRE -- Cancer Genetics, Inc. the Company Nasdaq: CGIX, a leader in drug discovery and preclinical oncology and immuno-oncology services, today announced that it has entered into securities purchase agreements with certain healthcare-focused institutional investors to raise approximately 17.5 million through the issuance of 2,777,778 shares of its common stock at a purchase price of 6.30 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about February 16, 2021, subject to the satisfaction of customary closing conditions. 